A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study-Reference-Cited by-同舟云学术

A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study

Published:2020 Issue: Volume:22 Page:100162
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Ernani Vinicius,Jahan Rahat,Smith Lynette M.,Marr Alissa S.,Kimbrough Sarah E.,Kos Mary E.,Tijerina Jolene,Pivovar Shannon,Lakshmanan Imayavaramban,Ketcham Marsha,Rauth Sanchita,Mallya Kavita,Nasser Mohd W,Jain Maneesh,Kessinger Anne,Batra Surinder K.,Ganti Apar Kishor

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J. Clin. Oncol.,2006

2. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;von Pawel;J. Clin. Oncol.,1999

3. DNA topoisomerases;Wang;Ann. Rev. Biochem.,1985

4. Protein-associated dna breaks in cells treated with adriamycin or ellipticine;Ross;Biochim. Biophys. Acta,1978

5. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian dna topoisomerase ii;Tewey;J. Biol. Chem.,1984

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways;Cancers;2022-11-26

2. Topotecan Reduces Neuron Death after Spinal Cord Injury by Suppressing Caspase-1-Dependent Pyroptosis;Molecular Neurobiology;2022-07-18

3. Microformulations and Nanoformulations of Doxorubicin for Improvement of Its Therapeutic Efficiency;Critical Reviews™ in Therapeutic Drug Carrier Systems;2020